Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 (FY2025)
Notice Concerning FY2025 Consolidated Results Variance,Dividend of Surplus(Resumption),and Reversal of General Reserve
Consolidated Financial Results for the Fiscal Year Ended December 31, 2025 (Under Japanese GAAP)
Notice Concerning Partial Amendments to the Articles of Incorporation
TAIKO PHARMA, Last Fiscal Year's Ordinary Profit Exceeds Expectations, 8% Increase in The Current Fiscal Year, Resuming Dividends at 3.3 Yen for the First Time in five terms., This Fiscal Year to Increase Dividend by 0.2 Yen
Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December 31, 2025 (Under Japanese GAAP)
Notice regarding the formulation of the Medium-Term Management Plan (FY2026-2028)
Notice Concerning Revisions to the Full-Year Consolidated Earnings Forecast
Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December 31, 2025 (FY2025)
TAIKO PHARMA, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 50%
The completion of liquidation of an overseas consolidated subsidiary(recording of extraordinary profit)and revision of consolidated earnings forecast
TAIKO PHARMA, Net Income Forecast for the Fiscal Year Revised Upward by 50%
Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2025 (FY2025)
Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending December 31, 2025 (Under Japanese GAAP)
TAIKO PHARMA, First Half Ordinary Profit Decreases by 96%, Apr-Jun Ordinary Profit Decreases by 97%
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2025 (FY2025)
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending December 31, 2025 (Under Japanese GAAP)
TAIKO PHARMA, Jan-Mar (1Q) Ordinary Profit Decreases by 95%
[Delayed]Consolidated Financial Results for the Fiscal Year Ended December 31, 2024 (FY2024)
Consolidated Financial Results for the Fiscal Year Ended December 31,2024(Under Japanese GAAP)